Global AI-based Clinical Trials Solution Provider Market Size, Share, and COVID-19 Impact Analysis, By Therapeutic Application (Oncology, CVD, Neurological Diseases or conditions, Metabolic diseases, Infectious diseases, and Others), By Clinical Trial Phase (Phase-I, Phase-II, and Phase-III), By End-use (Pharmaceutical Companies, Academia, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global AI-based Clinical Trials Solution Provider Market Size Forecasts to 2035

• The Global AI-based Clinical Trials Solution Provider Market Size Was Estimated at USD 2.13 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 22.03% from 2025 to 2035
• The Worldwide AI-based Clinical Trials Solution Provider Market Size is Expected to Reach USD 19.03 Billion by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

The global AI-based clinical trials solution provider market size was worth around USD 2.13 billion in 2024 and is predicted to grow to around USD 19.03 billion by 2035 with a compound annual growth rate (CAGR) of 22.03% from 2025 to 2035. The market growth is boosted by AI-driven platforms that are revolutionizing drug development by enhancing efficiency, reducing delays, and enabling decentralized trial models. Continued investment and collaboration are set to sustain long-term growth and innovation in the clinical trial landscape.

Market Overview 

The AI-based clinical trials solution provider market refers to a platform that uses artificial intelligence technologies to optimize and streamline different parts of the clinical trial process, including machine learning, natural language processing (NLP), and predictive analytics. These technologies improve trial efficiency, save costs, and speed up drug development timelines by assisting with tasks including patient recruiting, trial design, data monitoring, and outcome prediction.

Drug research is being revolutionized by AI-based clinical trial technologies that automate patient recruiting, optimize trial design, and provide real-time data monitoring. These tools improve accuracy, efficiency, and decision-making by utilizing machine learning, natural language processing, and predictive analytics. Regulatory compliance, risk identification, and intelligent patient matching are examples of current applications. The utilization of digital twins for trial simulation, wearable integration, and the growth of decentralized trials are examples of emerging trends. Blockchain for data security and IoT for ongoing patient monitoring are examples of future developments. All of these developments are contributing to the advancement of customized medicine and speeding up clinical trials.

Report Coverage

This research report categorizes the AI-based clinical trials solution provider market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the AI-based clinical trials solution provider market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the AI-based clinical trials solution provider market.

Driving Factors

The growing need for economical, successful medication development is driving the AI-based clinical trials solution provider market. The growing interest in AI-driven platforms is demonstrated by strategic investments and acquisitions like those made by Accenture and EQT. These systems are decreasing trial delays and improving results by enhancing real-time monitoring, trial design, and patient recruitment. The industry is being further stimulated by public-private partnerships and initiatives to lessen data bias. The implementation of AI in drug trials was further expedited by the COVID-19 pandemic, which resulted in a move toward decentralized and data-driven models. It is anticipated that this momentum would support the sector's long-term innovation and expansion.

Restraining Factors

The market growth is hindered by the high implementation costs and the requirement for a strong digital infrastructure, particularly in developing nations and smaller research groups. Significant obstacles are also presented by worries about algorithmic bias, data privacy, and the absence of established legal frameworks. Furthermore, incorporating AI tools into current trial workflows calls for specific knowledge, which might not be readily available.

Market Segmentation

The AI-based clinical trials solution provider market share is classified into therapeutic application, clinical trial phase, and end use.

• The oncology segment held the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the therapeutic application, the AI-based clinical trials solution provider market is classified into oncology, CVD, neurological diseases or conditions, metabolic diseases, infectious diseases, and others. Among these, the oncology segment held the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The segmental growth can be attributed to the use of AI-enabled technologies in oncology clinical trials, which is growing faster due to the increasing incidence of cancer worldwide. AI technologies improve trial matching and patient pre-screening, increasing productivity and trial success rates. This trend is emphasized by collaborations such as those between Deep Lens and Hematology-Oncology Associates. The cancer sector of AI-based clinical trials is expanding significantly as a result of these advancements.

• The phase-II segment accounted for the largest share in 2024 and is estimated to grow at a remarkable CAGR during the forecast period.

Based on the clinical trial phase, the AI-based clinical trials solution provider market is categorized into phase-I, phase-II, and phase-III. Among these, the phase-II segment accounted for the largest share in 2024 and is estimated to grow at a remarkable CAGR during the forecast period. The segmental growth can be attributed to a large number of registered clinical trials that are currently in their second phase.  The segment's rise is mostly due to the increasing usage of AI-based solutions for data collecting and analysis during drug trials. Additionally, because it makes it easier to refine, determine, and validate measurements connected to AI-based tools at this phase, this segment commands a higher revenue share.

• The pharmaceutical companies segment accounted for the largest share in 2024 and is estimated to grow at a remarkable CAGR during the forecast period.

Based on the end-use, the AI-based clinical trials solution provider market is categorized into pharmaceutical companies, academia, and others. Among these, the pharmaceutical companies segment accounted for the largest share in 2024 and is estimated to grow at a remarkable CAGR during the forecast period. The segmental growth can be attributed to the efficiency and accuracy of pharmaceutical R&D are being greatly improved by the increasing use of AI in drug discovery and development. AI suppliers and big pharmaceutical corporations are working together to speed up research and shorten the time it takes for new treatments to reach the market. An important development in the AI-driven pharmaceutical revolution is the collaboration between Sanofi, OpenAI, and Formation Bio. The future of drug development is anticipated to be redefined by such activities.

Regional Segment Analysis of the AI-based Clinical Trials Solution Provider Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the AI-based clinical trials solution provider market over the predicted timeframe.

North America is anticipated to hold the largest share of the AI-based clinical trials solution provider market over the predicted timeframe. The regional growth can be attributed to the precision medicine advancements are being propelled by Canada's robust healthcare system and investments in biotechnology and artificial intelligence. AI has the potential to transform real-time patient-trial matching, as evidenced by the creation of systems such as PMATCH.  These developments are speeding up clinical research results and improving individualized care.

Asia Pacific is expected to grow at a rapid CAGR in the AI-based clinical trials solution provider market during the forecast period. The region's growth is being driven by its sizable patient base and economic research setting. Innovation in the healthcare industry is being accelerated by the quick adoption of AI and encouraging government regulations. The region is attracting international biotech investments due to its expertise in areas such as infectious diseases and oncology. Asia Pacific is becoming more and more well-known in the world of clinical research due to its talented researchers and effective patient enrollment.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the AI-based clinical trials solution provider market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• IBM
• Unlearn.ai, Inc.
• Exscientia
• Saama
• Aitia
• Antidote Technologies, Inc.
• Verily (Google LLC)
• Phesi
• BioSymetrics, Inc.
• Deep6.ai
• Euretos
• Innoplexus
• Koneksa Health
• Mendel Health Inc.
• AiCure
• PHARMASEAL
• Others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Key Recent Development

• In May 2024, Phesi announced Version 2 of its award-winning Trial Accelerator, an AI-driven tool for clinical trial optimization, which includes data from 132 million patients. With powerful analytics spanning 400,000+ cohorts and 42 disease indications, the platform improves trial planning, site selection, and patient recruitment.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the AI-based clinical trials solution provider market based on the below-mentioned segments: 

Global AI-based Clinical Trials Solution Provider Market, By Therapeutic Application

• Oncology
• CVD
• Neurological Diseases or conditions
• Metabolic diseases
• Infectious diseases
• Others

Global AI-based Clinical Trials Solution Provider Market, By Clinical Trial Phase

• Phase-I
• Phase-II
• Phase-III

Global AI-based Clinical Trials Solution Provider Market, By End-use

• Pharmaceutical Companies
• Academia
• Others

Global AI-based Clinical Trials Solution Provider Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa